Inflammatory bowel disease: beyond the boundaries of the bowel

References

• Keren DF. Autoreactivity and altered immune responses in inflammatory bowel disease. Clin. Lab. Med.8, 325–336 (1988).
   PubMed Web of Science ®Google Scholar
• Mishina D, Katsel P, Brown ST, Gilberts EC, Greenstein RJ. On the etiology of Crohn’s disease. Proc. Natl Acad. Sci. USA93, 9816–9820 (1996).
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet369, 1627–1640 (2007).
   PubMed Web of Science ®Google Scholar
• Actis GC, Rosina F. Out-patient care for inflammatory bowel disease at a primary referral hospital in Turin. Minerva Gastroenterol. Dietol.56, 27–34 (2010).
   PubMedGoogle Scholar
• Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology136, 1182–1197 (2009).
   PubMed Web of Science ®Google Scholar
• Bell AJ, Price AB, Forbes A, Ciclitira PJ, Groves C, Nicholls RJ. Pre-pouch ileitis: a disease of the ileum in ulcerative colitis after restorative proctocolectomy. Colorectal Dis.8, 402–410 (2006).
   PubMedGoogle Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N. Engl. J. Med.361, 2066–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Actis GC, Ottobrelli A, Lavezzo B et al. Recurrent necro-inflammatory disease of multiple organs and colon. Dig. Dis. Sci.41, 2100–2105 (1996).
   PubMedGoogle Scholar
• Friedland MA, Weatherall DJ, Ledingham JGG. A chronic granulomatous syndrome of unknown origin. Medicine69, 325–331 (1990).
   PubMedGoogle Scholar
• Actis GC, Ottobrelli A, Baldi S et al. Mesalamine-induced lung injury in a patient with ulcerative colitis and a confounding autoimmune background. Mt Sinai J. Med.72, 136–140 (2005).
   PubMedGoogle Scholar
• Melum E, Franke A, Karlsen TH. Genome-wide association studies – a summary for the clinical gastroenterologist. World J. Gastroenterol.15, 5377–5396 (2009).
   PubMed Web of Science ®Google Scholar
• Guidi L, Marzo M, Felice C et al. New biological agents for the treatment of the high risk IBD patients. Eur. Rev. Med. Pharmacol. Sci.14, 342–346 (2010).
   PubMedGoogle Scholar
• Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol. Today14, 426–430 (1993).
   PubMedGoogle Scholar
• Lan RY, Mackay IR, Gershwin ME. Regulatory T-cells in the prevention of mucosal inflammatory diseases: patrolling the border. J. Autoimmun.29, 272–280 (2007).
   PubMed Web of Science ®Google Scholar
• Agrawal D, Rukkannagari S, Kethu S. Pathogenesis and clinical approach to extra-intestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol. Dietol.53, 233–248 (2007).
   PubMedGoogle Scholar
• Sheldon P. Rheumatoid arthritis and gut related lymphocytes: the iteropathy concept. Ann. Rheum. Dis.47, 697–700 (1988).
   PubMedGoogle Scholar
• Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol. Rev.223, 87–113 (2008).
   PubMed Web of Science ®Google Scholar
• Williams IR. CCR6 and CCL20: partners in intestinal immunity and lymphorganogenesis. Ann. NY Acad. Sci.1072, 52–61 (2006).
   PubMedGoogle Scholar
• Moon CM, Cheon JH, Kim SW et al. Association of signal transducer and activator of transcription 4 genetic variants with extra-intestinal manifestations in inflammatory bowel disease. Life Sci.86, 661–667 (2010).
   PubMedGoogle Scholar
• Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap syndromes in inflammatory bowel disease. World J. Gastroenterol.14, 331–337 (2008).
   PubMed Web of Science ®Google Scholar
• Szabo N, Lukacs S, Kulcsar I et al. Association of idiopathic inflammatory myopathy and Crohn’s disease. Clin. Rheumatol.28, 99–101 (2009).
   PubMed Web of Science ®Google Scholar
• Balamtekin N, Gűrakan F, Ozen S, Oguz B, Talim B. Ulcerative colitis associated with Takayasu’s arteritis in a child. Acta Paediatr.98, 1368–1371 (2009).
   PubMedGoogle Scholar
• Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern California – managed care organization. Am. J Gastroenterol.102, 1429–1435 (2007).
   PubMed Web of Science ®Google Scholar
• Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J. Gastroenterol. Hepatol.25, 325–333 (2010).
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology129, 827–836 (2005).
   PubMed Web of Science ®Google Scholar
• Mackay IR. Clustering and commonalities among autoimmune diseases. J. Autoimmun.33, 170–177 (2009).
   PubMed Web of Science ®Google Scholar
• Lang B, Weber S, Maas D. Autoimmune hemolytic anemia in ulcerative colitis. Report on 7 cases, possible treatment, and review of the literature. Schweiz Med. Wochenschr.115, 897–902 (1985).
   PubMedGoogle Scholar
• Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn’s disease. Am. J. Gastroenterol.104, 117–124 (2009).
   PubMed Web of Science ®Google Scholar
• Burak KW, May GR. C1 Inhibitor deficiency and angioedema of the small intestine masquerading as Crohn’s disease. Can. J. Gastroenterol.14, 349–351 (2000).
   PubMedGoogle Scholar
• Actis GC, Lagget M, Ciancio A et al. Recurrent Sweet’s syndrome in reactivated Crohn’s disease. J. Clin. Gastroenterol.21, 317–319 (1995).
   PubMedGoogle Scholar
• Paoluzi OA, Crispino P, Amantea A et al. Diffuse febrile dermatosis in a patient with active ulcerative colitis under treatment with steroids and azathioprine: a case of Sweet syndrome. Case report and review of literature. Dig. Liver Dis.36, 361–366 (2004).
   PubMedGoogle Scholar
• Kahraman A, Miller M, Maldonado-Lopez E, Baba HA, Treichel U, Gerken G. A 55-year-old woman with thymoma and hypogammaglobulinemia (Good syndrome), ulcerative colitis, and citomegalovirus infection. Med. Klin. (Munich)104, 150–154 (2009).
   PubMedGoogle Scholar
• Godt C, Regnery A, Schwarze B, Junker K, Porschen R. A rare cause of ulcerative colitis–diarrhea and perianal bleeding due to post-transplant lymphoproliferative disorder (PTLD). Z. Gastroenterol.47, 283–287 (2009).
   PubMedGoogle Scholar
• Agarwal S, Mayer L. Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes. J. Allergy Clin. Immunol.124, 658–664 (2009).
   PubMedGoogle Scholar
• Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract. Res. Clin. Gastroenterol.24, 157–165 (2010).
   PubMed Web of Science ®Google Scholar
• Fouache D, Goëb V, Massy-Guillemant N et al. Paradoxical adverse events of anti-tumor necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology48, 761–764 (2009).
   PubMed Web of Science ®Google Scholar
• Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzioğlu E. Development of Crohn’s disease following anti-tumor necrosis factor therapy (etanercept). Colorectal Dis.10, 953–954 (2008).
   PubMed Web of Science ®Google Scholar
• Wiegering V, Morbach H, Dick A, Girschick HJ. Crohn’s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol. Int.30, 801–804 (2010).
   PubMed Web of Science ®Google Scholar
• Hvas CL, Kelsen J, Agnholt J, Dige A, Christensen LA, Dahlerup JF. Discrete changes in circulating regulatory T-cells during infliximab treatment of Crohn’s disease. Autoimmunity43, 325–333 (2010).
   PubMed Web of Science ®Google Scholar
• Boschetti G, Nancey S, Sardi F et al. Therapy with anti-TNF α antibody enhances number and function of Foxp3+ regulatory T-cells in inflammatory bowel diseases. Inflamm. Bowel Dis.17, 160–170 (2011).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Deventer S, Schreiber S. Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease – focus on selective adhesion molecule inhibition. Aliment. Pharmacol. Ther.17, 1435–1450 (2003).
   PubMed Web of Science ®Google Scholar
• Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F. NOD2-associated diseases: bridging innate immunity and autoinflammation. Clin. Immunol.134, 251–261 (2010).
   PubMed Web of Science ®Google Scholar
• Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J. Gastroenterol.14, 390–400 (2008).
   PubMed Web of Science ®Google Scholar
• Behr MA. The path to Crohn’s disease: is mucosal pathology a secondary event? Inflamm. Bowel Dis.16, 896–902 (2010).
   PubMed Web of Science ®Google Scholar
• Henckaerts L, Vermeire S. NOD-2/CARD15 disease associations other than Crohn’s disease. Inflamm. Bowel Dis.13, 235–241 (2007).
   PubMed Web of Science ®Google Scholar
• Fireman E, Masarwy F, Groisman G et al. Induced sputum eosinophilia in ulcerative colitis patients: the lung as a mirror image of intestine. Respir. Med.103, 1025–1032 (2009).
   PubMed Web of Science ®Google Scholar
• Maltby S, Wohlfarth C, Gold M, Zbytnuik L, Hughes MR, McNagny KM. CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis. Am. J. Pathol.177, 1244–1254 (2010).
   PubMedGoogle Scholar
• Műller-Ladner U, Alten R, Heiligenhaus A et al. ‘TRECID’, TNF-α related chronic inflammatory diseases – bridging concept. Dtsch. Med. Wochenschr.134, 2132–2136 (2009).
   PubMedGoogle Scholar
• Marzo-Ortega H, McGonagle D, O’Connor P. Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Am. Rheum. Dis.62, 74–76 (2003).
   Google Scholar
• Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology124, 1774–1785 (2003).
   PubMed Web of Science ®Google Scholar
• Leung Y, Geddes M, Storek J, Panaccione R, Beck PL. Hematopoietic cell transplantation for Crohn’s disease: is it time? World J. Gastroenterol.12, 6665–6673 (2006).
   PubMed Web of Science ®Google Scholar
• Burt RK, Craig RM, Milanetti F et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn’s disease: long-term follow-up. Blood116, 6123–6132 (2010).
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr, Kerr IM, Stark JR. JAK–STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science264, 1415–1421 (1994).
   PubMed Web of Science ®Google Scholar
• Fu XY. STAT3 in immune responses and inflammatory bowel diseases. Cell Res.16, 214–219 (2006).
   PubMed Web of Science ®Google Scholar
• Franke A, Balschun T, Karlsen TH et al. Replication of signals from recent studies of Crohn’s disease identifies previously unknown disease loci for ulcerative colitis. Nat. Genet.40, 713–715 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson CA, Massey DC, Barrett JC et al. Investigation of Crohn’s disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology136, 523–529 (2009).
   PubMed Web of Science ®Google Scholar
• Egwuagu CE. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine47, 149–156 (2009).
   PubMed Web of Science ®Google Scholar
• Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J. Immunol.172, 567–576 (2004).
   PubMed Web of Science ®Google Scholar
• Glocker EO, Kotlarz D, Boztug K et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med.361, 2033–2045 (2009).
   PubMed Web of Science ®Google Scholar
• Freeman AF, Holland SM. Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. Pediatr. Res.65, R32–R37 (2009).
   Google Scholar
• Carthew RW. Gene regulation by micro-RNAs. Curr. Opin. Genet. Dev.16, 203–208 (2006).
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with anti-sense complementarity to lin-14. Cell75, 843–854 (1993).
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes mir-15 and mir-16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA99, 15524–15529 (2002).
   PubMed Web of Science ®Google Scholar
• Iborra M, Bernuzzi F, Invernizzi P, Danese S. Micro-RNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmunity Rev. DOI: 10.1016/j.autrev.2010.07.002 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Du T, Zamore PD. MicroPrimer: the biogenesis and function of micro-RNA. Development132, 4645–4652 (2005).
   PubMed Web of Science ®Google Scholar
• Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of mi-RNA mediated gene silencing. Cell132, 9–14 (2008).
   PubMed Web of Science ®Google Scholar
• Wu F, Zikusoka M, Trindade A et al. Micro-RNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide -2-α. Gastroenterology135, 1624–1635 (2008).
   PubMed Web of Science ®Google Scholar
• Landi D, Gemignani F, Naccarati A et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis29, 579–584 (2008).
   PubMed Web of Science ®Google Scholar
• Wu F, Guo Nj, Tian H et al. Peripheral blood micro-RNAs distinguish active ulcerative colitis and Crohn’s disease. Inflamm. Bowel Dis.17, 241–250 (2011).
   PubMed Web of Science ®Google Scholar
• Wu F, Zhang S, Dassopoulos T et al. Identification of micro-RNAs associated with ileal and colonic Crohn’s disease. Inflamm. Bowel Dis.16, 1729–1738 (2010).
   PubMed Web of Science ®Google Scholar
• Fasseu M, Tréton X, Guichard C et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One5(10), pii e13160 (2010).
   Google Scholar
• Wei B, Pei G. Micro-RNAs: critical regulators in Th17 cells and players in diseases. Cell. Mol Immunol.7(3), 175–181 (2010).
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho J. Interleukin 23/Th17 pathways and inflammatory bowel disease. Inflamm. Bowel Dis.15, 1090–1100 (2009).
   PubMed Web of Science ®Google Scholar
• Rozin AP, Hasin T, Toledano K, Guralnik L, Balbir-Gurman A. Seronegative polyarthritis as severe systemic disease. Neth. J. Med.68, 236–241 (2010).
   PubMedGoogle Scholar
• Yang GX, Lian ZX, Chuang YH et al. Adoptive transfer of CD8(+) T-cells from transforming growth factor β receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology47, 1974–1982 (2008).
   PubMed Web of Science ®Google Scholar
• Mackay IR, Leskovsek NV, Rose NR. The odd couple: a fresh look at autoimmunity and immunodeficiency. J. Autoimmun.35, 199–205 (2010).
   PubMedGoogle Scholar
• Tomita T, Kanai T, Nemoto Y et al. Systemic, but not intestinal, Il-7 is essential for the persistence of chronic colitis. J. Immunol.180, 383–390 (2008).
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn’s disease: beyond antagonists of tumor necrosis factor. Lancet372(9632), 67–81 (2008).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of ustekinumab, a human interleukin -12/23 monoclonal antibody in patients with moderate-to-severe Crohn’s disease. Gastroenterology135, 1130–1141 (2008).
   PubMed Web of Science ®Google Scholar
• Koutruba N, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther. Klin. Risk Manag.6, 123–141 (2010).
   PubMed Web of Science ®Google Scholar
• Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut DOI: 10.1136/gut.2009.199679 (2011) (Epub ahead of print).
   Google Scholar
• Sewell GW, Marks DJ, Segal AW. The immune-pathogenesis of Crohn’s disease: a three-stage model. Curr. Opin. Immunol.21, 506–513 (2009).
   PubMed Web of Science ®Google Scholar
• Sokol H, Seksik P, Carrat F et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut59, 1363–1368 (2010).
   PubMed Web of Science ®Google Scholar
• Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat. Immunol.12, 5–9 (2011).
   PubMed Web of Science ®Google Scholar
• Lakhan SE, Kirchgessner A. Gut inflammation in chronic fatigue syndrome. Nutr. Metab. (Lond.7, 79 (2010).
   PubMedGoogle Scholar
• Xueliang Li. Importance of investigation on inflammatory bowel disease in China. Inter. Med.48, 251–252 (2009).
   PubMedGoogle Scholar
• Arijs I, Li K, Toedter G et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut58, 1612–1619 (2009).
   PubMed Web of Science ®Google Scholar
• Rosenstiel P, Sina C, Franke A, Schreiber S. Towards a molecular risk map – recent advances on the etiology of inflammatory bowel disease. Semin. Immunol.21, 334–345 (2009).
   PubMed Web of Science ®Google Scholar